Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Females are underrepresented in randomized controlled trials of mechanical circulatory support in cardiogenic shock.

Cardiovascular revascularization medicine : including molecular interventions·2026
Same author

Transmembrane protein 53 craniotubular dysplasia (OMIM # 619727): The skeletal disease and consequent blindness of this new disorder.

Bone·2024
Same author

Mitofusin 2 plays a critical role in maintaining the functional integrity of the neuromuscular-skeletal axis.

Bone·2024
Same author

Coalescing expansile skeletal disease: Delineation of an extraordinary osteopathy involving the IFITM5 mutation of osteogenesis imperfecta type V.

Bone·2020
Same author

Iron replacement ameliorates hypophosphatemia in autosomal dominant hypophosphatemic rickets: A review of the role of iron.

Bone·2019
Same author

Oxidation-specific epitopes restrain bone formation.

Nature communications·2018
Same journal

Tirzepatide as a multi-organ integrator in metabolic diseases: a review of molecular mechanisms and clinical translation.

Endocrine·2026
Same journal

Effects of a single-dose denosumab on glucose and lipid homeostasis in young infertile men.

Endocrine·2026
Same journal

Ultrasound-guided thermal ablation for papillary thyroid microcarcinoma with calcifications: short-term imaging outcomes.

Endocrine·2026
Same journal

Diabetic gastroparesis: pathophysiology and impact on insulin timing choices.

Endocrine·2026
Same journal

Liquid biopsies for BRAF V600E assessment and monitoring in anaplastic thyroid carcinoma: a real-world study of a tertiary cancer center.

Endocrine·2026
Same journal

Interpreting the TIR 3B nomogram as a rule-in rather than rule-out tool.

Endocrine·2026
See all related articles

Related Experiment Video

Updated: May 26, 2026

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats
05:55

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats

Published on: September 27, 2024

Glucocorticoid-induced osteonecrosis.

Robert S Weinstein1

  • 1Division of Endocrinology and Metabolism, Center for Osteoporosis and Metabolic Bone Diseases, Central Arkansas Veterans Healthcare System, University of Arkansas for Medical Sciences, Little Rock, AR 72205-7199, USA. weinsteinroberts@uams.edu

Endocrine
|December 16, 2011
PubMed
Summary
This summary is machine-generated.

Glucocorticoids commonly cause nontraumatic osteonecrosis by inducing osteocyte apoptosis, a bone cell death that leads to femoral head collapse. Bisphosphonates may help manage this condition.

More Related Videos

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
11:47

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders

Published on: June 8, 2014

Related Experiment Videos

Last Updated: May 26, 2026

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats
05:55

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats

Published on: September 27, 2024

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
11:47

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders

Published on: June 8, 2014

Area of Science:

  • Bone biology
  • Endocrinology
  • Orthopedics

Background:

  • Glucocorticoid administration is a frequent, yet often overlooked, cause of nontraumatic osteonecrosis.
  • Glucocorticoid-induced osteonecrosis affects 9-40% of patients on long-term therapy and can occur with short-term high doses or intra-articular injections.
  • Osteonecrosis is characterized by osteocyte apoptosis, a primary lesion that impairs bone remodeling and mechanosensory function.

Purpose of the Study:

  • To highlight glucocorticoid-induced osteonecrosis as a significant clinical issue.
  • To explain the pathological mechanism of glucocorticoid-induced osteonecrosis.
  • To review the potential therapeutic benefits of bisphosphonates.

Main Methods:

  • Literature review and synthesis of existing evidence on glucocorticoid-induced osteonecrosis.
  • Histopathological analysis of osteonecrosis.
  • Clinical evidence review for bisphosphonate efficacy.

Main Results:

  • Glucocorticoid excess leads to osteocyte apoptosis, disrupting the osteocyte-lacunar-canalicular system.
  • This apoptosis, coupled with reduced bone remodeling, initiates a cascade leading to femoral head collapse.
  • Bisphosphonates show promise in reducing pain, improving mobility, and delaying joint collapse in affected patients.

Conclusions:

  • Glucocorticoid-induced osteonecrosis is a serious complication resulting from osteocyte apoptosis and impaired bone remodeling.
  • Early recognition and intervention are crucial for managing this condition.
  • Bisphosphonates represent a potential therapeutic strategy for mitigating the effects of glucocorticoid-induced osteonecrosis.